Skip to Content

Roy B. Jones, M.D.,Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Roy Jones is Professor of Medicine in the Department of Blood and Marrow Transplantation, MD Anderson Cancer Center. He received undergraduate and M.D. degrees from Duke University and a Ph.D. in medicinal chemistry from Emory University. Prior to coming to MD Anderson in 2002, he was director of informatics for the University of Colorado Cancer Center, Professor of Medicine, University of Colorado Health Sciences Center, and director of the Bone Marrow Transplant Program. Dr. Jones has served as a reviewer on several NCI Study Sections including Subcommittee D (Clinical Program Project Grants) and CONC (Clinical Oncology Study Section). 

 Dr. Jones is board certified in Internal Medicine and Medical Oncology. His clinical research interests are the pharmacology of high-dose chemotherapy,the developmental therapeutics of hematopoietic stem cell transplantation, and computerized approaches to the design, approval, and management of clinical trials. He is the author of more than 150 book chapters and original articles in the areas of pharmacology of intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). His clinical interests include the treatment of a variety of cancers with HSCT. 

Research Interests

Novel Alkylating-agent based high-dose chemotherapy regimens; informatics strategies to support BMT translational research

Office Address

The University of Texas MD Anderson Cancer Center
Dept of Stem Cell Transplantation & Cellular Therapy
1515 Holcombe Bvld
Unit Number: Unit 423
Houston, TX 77030
Room Number: FC5.3036

Education & Training

Degree-Granting Education

1975 Duke University Medical Center, Durham, NC, MD
1972 Emory University, Atlanta, GA, MS
1972 Emory University, Atlanta, GA, PHD
1967 Duke University, Durham, NC, BS

Postgraduate Training

1/1980-12/1981 Resident, Internal Medicine, Gerogetown University Medical Center, Washington, DC
1/1979-1/1980 Resident, Georgetown University Medical Center, Washington, DC
1/1979-1/1980 Investigator, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD
1/1977-1/1978 Clinical Associate, National Cancer Institute, Bethesda, MD
1/1976-1/1977 Intern in Medicine, Duke University Medical Center, Durham, NC
1/1975-12/1975 Hematology Fellow, Duke University Medical Center, Durham, NC

Board Certifications

1/1981 American Board of Medical Oncology
1/1980 American Board of Internal Medicine

Honors and Awards

2001-present Voted, Best Doctors in America

Selected Publications

Peer-Reviewed Original Research Articles

1. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 17(3):412-20, 3/2011. e-Pub 7/2010. PMID: 20674757.
2. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 3/2011. e-Pub 12/2010. PMID: 21156844.
3. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol 29(3):294-302, 1/2011. e-Pub 12/2010. PMCID: PMC3056464.
4. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14(6):672-84, 6/2008. PMID: 18489993.
5. Jones RB, Vredenburgh JJ, Coniglio D, Broadwater G,. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 12(2):195-203, 2/2006. PMID: 16443517.
6. Jones R, Nieto Y, Rizzo JD, Wall D, Wingard JR, McCarthy P, Hahn T, Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 11(11):819-22, 11/2005. PMID: 16275587.
7. Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 10(8):2609-17, 4/2004. PMID: 15102662.
8. Jones RB. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res 112:305-22, 2002. PMID: 12481722.

Book Chapters

1. Jones RB, Shpall EJ,Champlin, R. Hematopoietic Cell Transplantation. In: Bone Marrow Transplantation, 879-897, 2006.
2. Tew Kenneth D., Colvin O.M, Jones Roy B. Clinical and High-Dose Alkylating Agents. In: Cancer Chemotherapy & Biotherapy; Principles and Practice,, fourth edition, 283-309, 2005.

Last updated: 7/21/2014